/MGRX
MGRX Stock - Mangoceuticals, Inc.
Healthcare|Medical - Healthcare Information ServicesNASDAQ
$0.71-45.57%
$0.60 (-45.57%) • Dec 19
39
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.3
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.17
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.78
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MGRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.71 – $0.72
TARGET (TP)$0.82
STOP LOSS$0.66
RISK/REWARD1:2.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.57
52W High$6.15
52W Low$0.52
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $615,873 | $731,493 | $8,939 | N/A |
| Gross Profit | $379,964 | $431,501 | $4,850 | N/A |
| Gross Margin | 61.7% | 59.0% | 54.3% | N/A |
| Operating Income | $-7,972,000 | $-9,218,890 | $-1,991,582 | $-17,520 |
| Net Income | $-8,706,000 | $-9,212,417 | $-1,998,055 | $-17,701 |
| Net Margin | -1413.6% | -1259.4% | -22352.1% | N/A |
| EPS | $-4.40 | $-8.58 | $-1.73 | $-0.02 |
Company Overview
Mangoceuticals, Inc. focuses on develops, markets, and sells various men's wellness products and services through a telemedicine platform. It offers erectile dysfunction products under the Mango brand name. The company sells its products through online website mangorx.com. Mangoceuticals, Inc. was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
MGRXBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.69
Q4 2025
EPS Surprise History
Q2 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 14, 2025 | — | $-0.69 | — | — |
Q3 2025 | Aug 14, 2025 | — | $-0.57 | — | — |
Q2 2025 | May 15, 2025 | — | $-1.29 | — | — |
Q1 2025 | Mar 20, 2025 | — | $-1.01 | — | — |
Q4 2024 | Nov 14, 2024 | — | $-0.99 | — | — |
Q3 2024 | Aug 14, 2024 | — | $-1.35 | — | — |
Q2 2024 | May 15, 2024 | — | $-1.50 | — | — |
Q2 2024 | Apr 1, 2024 | — | $-1.95 | — | — |
Q4 2023 | Oct 27, 2023 | — | $-1.65 | — | — |
Q3 2023 | Jul 28, 2023 | — | $-0.14 | — | — |
Q2 2023 | May 9, 2023 | — | $-3.41 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.76 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-1.00 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.33 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.02 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.02 | — | — |
Latest News
Mangoceuticals shares are trading lower. The company announced up to a $100 million Solana-focused digital asset treasury strategy.
📉 NegativeBenzinga•Dec 19, 2025, 02:16 PM
Mangoceuticals launches up to $100M Solana-focused digital asset treasury
📈 PositiveSeeking Alpha•Dec 19, 2025, 02:09 PM
Mangoceuticals Announces Up To $100M Solana-Focused Digital Asset Treasury Strategy In Partnership With Cube Group
📈 PositiveBenzinga•Dec 19, 2025, 12:31 PM
Mangoceuticals Announces $2.5M Registered Direct Offering, Selling 1.93M Common Units At $1.295 And Pre-Funded Units
📉 NegativeBenzinga•Dec 18, 2025, 01:42 PM
Mangoceuticals, Inc. Announces Registered Direct And Private Placement Transactions, Gross Proceeds $2.5M
📈 PositiveBenzinga•Dec 18, 2025, 01:40 PM
Mangoceuticals plunges after denying Lilly, Novo partnerships
📉 NegativeSeeking Alpha•Nov 14, 2025, 12:18 PM•Also: ,
Reported Earlier, Mangoceuticals Clarifies That New Weight Management Programs Offer Patients Reliable Access To Eli Lilly And Novo Nordisk Branded GLP 1 Medications
📈 PositiveBenzinga•Nov 14, 2025, 08:07 AM•Also: ,
Mangoceuticals shares are trading lower after Novo Nordisk and Eli Lilly reportedly said they have no affiliation with the company's telehealth platform, refuting its earlier weight-loss partnership claims.
📉 NegativeBenzinga•Nov 13, 2025, 07:28 PM•Also: ,
Reuters Reports: Novo Nordisk, Eli Lilly Spokespeople Say The Companies Have No Affiliation With Telehealth Platform Mangoceuticals, In Response To Its Press Release On Weight-Loss Partnerships
➖ NeutralBenzinga•Nov 13, 2025, 07:05 PM•Also: ,
MGRX stock has given up its prior gain. Mangoceuticals shares were trading higher after the company launched MangoRx Direct and PeachesRx Direct to provide direct access to Zepbound and Wegovy.
➖ NeutralBenzinga•Nov 13, 2025, 04:58 PM
Lilly, Novo in pact with Mangoceuticals for direct sales of weight loss drugs
📈 PositiveSeeking Alpha•Nov 13, 2025, 01:00 PM•Also: ,
Market-Moving News for November 13th
➖ NeutralBenzinga•Nov 13, 2025, 12:38 PM•Also: ,
Mangoceuticals shares are trading higher after the company launched MangoRx Direct and PeachesRx Direct to provide direct access to Zepbound and Wegovy.
📈 PositiveBenzinga•Nov 13, 2025, 12:03 PM
Mangoceuticals Launches MangoRx Direct And PeachesRx Direct, Which Will Provide Direct Access To Zepbound And Wegovy
📈 PositiveBenzinga•Nov 13, 2025, 12:02 PM
Mangoceuticals Files Trademark Application On November 6, 2025 Titled 'MULTI-DAT' For Virtual currency trading services; Financial Exchange Of Virtual Currency; Financial Trading Of Virtual Currency; Providing Financial Information In The Field Of Virtual Currency; Providing Financial Advisory Services In The Field Of Virtual Currency; Electronic Transfer Of Virtual Currencies; Investment Fund Management Services; Cryptocurrency Exchange Services Featuring Blockchain Technology
📈 PositiveBenzinga•Nov 10, 2025, 03:31 PM
Frequently Asked Questions about MGRX
What is MGRX's current stock price?
Mangoceuticals, Inc. (MGRX) is currently trading at $0.71 per share. The stock has moved -45.57% today.
What is the analyst price target for MGRX?
No analyst price targets are currently available for this stock.
What sector is Mangoceuticals, Inc. in?
Mangoceuticals, Inc. operates in the Healthcare sector, specifically within the Medical - Healthcare Information Services industry. The company is traded on the NASDAQ exchange.
What is MGRX's market cap?
Mangoceuticals, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does MGRX pay dividends?
No, Mangoceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorASBP
Aspire Biopharma Holdings, Inc.
$0.10
Mkt Cap: $0.0B
CASI
CASI Pharmaceuticals, Inc.
$0.81
Mkt Cap: $0.0B
CING
Cingulate Inc.
$3.97
Mkt Cap: $0.0B
CLSD
Clearside Biomedical, Inc.
$1.00
Mkt Cap: $0.0B
ENTO
Entero Therapeutics, Inc.
$1.98
Mkt Cap: $0.0B
FEMY
Femasys Inc.
$0.86
Mkt Cap: $0.0B
HCTI
Healthcare Triangle, Inc.
$1.93
Mkt Cap: $0.0B
PALI
Palisade Bio, Inc.
$1.83
Mkt Cap: $0.3B
TOI
The Oncology Institute, Inc.
$3.50
Mkt Cap: $0.3B
VSEE
VSee Health, Inc.
$0.44
Mkt Cap: $0.0B
Explore stocks similar to MGRX for comparison